Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CymaBay Therapeutics, Inc.

http://www.cymabay.com

Latest From CymaBay Therapeutics, Inc.

With 2023's Largest Indian IPO, Mankind Listing Watched; GPCR-Based Candidate Enters Trials

Scrip takes a look at what a listing of Mankind Pharma, which has thrice the revenues of Pfizer’s India unit and the fourth largest domestic pharma sales, would mean. A GPCR-based candidate against type-2 diabetes and obesity is in Phase I trials and a search on India’s trial registry reveals a study for an ayurvedic preparation against diabetes

Commercial Financing

Serum-Biocon Deal Sees COVID Reality Tweak Even As Oxford’s Malaria Vaccine Holds Promise

Gains from its COVID-19 vaccine made Serum Institute’s founder the world’s richest healthcare billionaire. But the demand for boosters hasn’t materialized as expected, leading to a deal with Biocon being tweaked. Meanwhile, gains from India’s first indigenously-developed HPV vaccine and Oxford-partnered malaria vaccine seem imminent.

Commercial Coronavirus COVID-19

HPV Vaccines – The Journey So Far And Long Road Ahead

HPV vaccines have come a long way since their launch in 2006, though not without their share of bumps and misinformation campaigns. US pediatric infectious disease specialist, Dr Kenneth Alexander, talks to Scrip about how data has evolved, why the US may not be the best example to emulate for HPV vaccination and new products on the horizon, among other topics.

Vaccines Commercial

Whiteboarding Ideas From Novartis, Novo To Address India’s Elephants In The Room, ‘On Streets’

Senior VPs from Novartis and Novo Nordisk offered suggestions ranging from protecting IP and fixing the perception of “elephants roaming the streets,” to “fit for purpose” global development plans to improve the research landscape in India, during a recent webinar, which also saw academia weighing in on various issues.

Research & Development India
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Metabolex, Inc.
    • Transplantation Technology, Inc.
    • Transtech Corporation
    • Transtech Medical, Inc.
UsernamePublicRestriction

Register